Cannabis in clinical practice - Harm reduction education & safety of our patients

Presented by Casara Andre, DVM, cVMA

Continuing education questionnaire

CE credit: 1

Nom

Questions

1. Harm Reduction Education (HRE) around cannabis is an important part of ensuring patient safety. *
2. Education should always be provided when: *
3. The patient safety component of HRE includes which of the following? *
4. Because cannabidiol (CBD) has been shown to be a Cytochrome P450 inhibitor, it should never be used concurrently with other medications that rely on the same metabolic pathway. *
5. Many cannabis products marketed for pet use are available on the black market. These products: *
6. The emerging market includes edible cannabis products. These products carry a greater risk to pets due to their high level of appeal, significant THC content, and potential for coexisting toxins such as xylitol, chocolate, raisins, etc. *
7. In veterinary medicine, the use of products with THC should always be avoided due to the risk of THC intoxication. *
8. Maintaining complete medical histories that document the use of cannabis and the advice provided is important in order to: *
9. As with any other chronic medication, it should be recommended to obtain a baseline examination and lab work prior to initiating therapy, followed by regular (q3-6m) re-evaluations, as determined by the individual case. *
10. Veterinarians should strive to contribute to community knowledge through the observation, record keeping, and sharing of knowledge gained through patients receiving cannabis for medical purposes. *